F20-F29
Conditions
Interventions
Group 1: As this study is a 5-year follow-up of an interventional study, the original intervention arms are described here once more. However, no new participants will be recruited for the current stu
Sponsors
Universitätsklinikum Hamburg-EppendorfKlinik und Poliklinik für Psychiatrie und Psychotherapie
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: This trial does not aim to recruit any new subjects, but rather to contact and reassess previously included study participants. 1) Schizophrenic spectrum disorder (ICD-F2x, verified using the MINI) 2) Ability to consent
Exclusion criteria
Exclusion criteria: 1) Intelligence: IQ < 70, measured with a vocabulary test (WST) 2) Rating for uncooperative behaviour and hostility = 5 on the PANSS scale (range: 1-7; G8, P7) 3) Acute suicidality 4) Current substance and alcohol dependence, except tobacco (i.e. abstinence < 6 months; substance and alcohol abuse are tolerated) 5) neurological or medical disease that may cause the psychotic symptoms 6) Participation in MCT+ within the last 12 months 7) Insufficient knowledge of German for participation in MCT+ 8) insufficient testability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive symptoms 5 years after the start of the intervention, measured by the Psychotic Symptom Rating Scales (PSYRATS) positive score. The PSYRATS is a semi-structured interview that covers quantitative and qualitative aspects of delusions and hallucinations including measures of conviction and suffering. The difference in PSYRATS score from T0-T3 (5-year follow-up) for delusions and hallucinations serves as the primary outcome parameter. The validity of the PSYRATS has been repeatedly demonstrated in psychotic patients. The original study included three points of measurement: Baseline, post-test, (6 weeks after baseline), and a follow-up test (6 months later). These are now being supplemented by a 5-year follow-up (T3). | — |
Secondary
| Measure | Time frame |
|---|---|
| The Positive and Negative Syndrome Scale (PANSS) is a 30 item scale, which measures positive symptoms, negative symptoms and general psychopathological factors via a semi-structured interview. Additional secondary outcomes are assessed by the following methods: The Fish Test is a computer-based variant of the classical beads task, which measures the jumping to conclusions bias. In addition, the Dice-Task, a web-based computerized dice game that records how people collect information, is carried out. The Personal and Social Performance Scale (PSP) is a scale that measures functional impairment in patients with schizophrenia. The Calgary Depression Rating Scale (CDSS) measures depressive symptoms in the context of schizophrenia. The Negative Symptom Assessment - 4 (NSA-4) interview measures the psychotic negative symptoms. The Beck Cognitive Insight Scale (BCIS) measures the patient's ability to distance themselves from and reflect on subjective cognitive biases. The WHO Quality of Life (WHOQOL-BREF) Scale measures the subjective quality of life of patients. The Obsessive-Compulsive Inventory - Revised (OCI-R) measures the degree of impairment due to obsessive thoughts and compulsions. The Rosenberg Scale measures global self-esteem. The 9-item Patient Health Questionnaire (PHQ-9) is a screening tool for determining the severity of depressive symptoms. In addition, memory performance is assessed using the Rivermead Behavioural Memory Test (short and long-term memory). The original three measurement points baseline, post-test (6 weeks after the baseline) and follow-up testing (6 months later) are now supplemented by a 5-year follow-up (T3). The differences in the score of the above mentioned instruments of T0 vs. T3 serve as secondary outcome parameters. | — |
Countries
Germany
Contacts
Public ContactSteffen Moritz
Universitätsklinikum Hamburg-Eppendorf
Outcome results
None listed